By PPN News Staff
The FDA approved pneumococcal 15-valent conjugate vaccine (PCV15, Vaxneuvance, Merck) to prevent invasive disease caused by 15 serotypes of Streptococcus pneumoniae in adults ages 18 years and older.
The Advisory Committee on Immunization Practices is expected to meet in October to discuss and make recommendations on the use of the vaccine in adults.